2016-2017 Arkansas mumps outbreak in a close-knit community: Assessment of the economic impact and response strategies.
Arkansas Marshallese
Cost of outbreak
Economic burden
Mumps
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
05 02 2020
05 02 2020
Historique:
received:
14
07
2019
revised:
25
11
2019
accepted:
26
11
2019
pubmed:
11
12
2019
medline:
9
3
2021
entrez:
11
12
2019
Statut:
ppublish
Résumé
On August 8, 2016, a confirmed case of mumps was reported to the Arkansas Department of Health (ADH) in an adult resident of Springdale, Arkansas. By July 2017, nearly 3,000 cases of mumps were reported to ADH from 37 of the 75 counties in Arkansas. Over 50% of cases were in the Arkansas Marshallese community, a close-knit community characterized by large, and extended families sharing the same living space and communal activities. In a statewide effort, ADH collaborated with CDC, the Republic of the Marshall Island's (RMI) Ministry of Health, and the Arkansas Department of Education (ADE) to rapidly respond to and contain the outbreak. We assessed the economic burden to ADH of the outbreak response in terms of containment and vaccination costs, as well as response costs incurred by CDC, RMI, and ADE. The 2016-2017 Arkansas mumps outbreak was the second largest US mumps outbreak in over 30 years and was unique in size, spread, and population affected. Total public health response costs as a result of the outbreak were over $2.1 million, approximately $725 per case. The costs incurred to control this outbreak reflect the response strategies tailored to the affected populations, including consideration of social, cultural, and political factors in controlling transmission and requirements of distinctive strategies for public health outreach. Aside from the burden these outbreaks have on the affected population, we demonstrate the potential for high economic burden of these outbreaks to public health.
Identifiants
pubmed: 31818532
pii: S0264-410X(19)31620-2
doi: 10.1016/j.vaccine.2019.11.066
pmc: PMC8963766
mid: NIHMS1789116
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1481-1485Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Infect Dis. 2019 Feb;19(2):185-192
pubmed: 30635255
MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34
pubmed: 23760231
J Public Health Manag Pract. 2020 Mar/Apr;26(2):116-123
pubmed: 30807459
Med Anthropol Q. 2017 Sep;31(3):422-439
pubmed: 28409861
MMWR Suppl. 1989 Dec 29;38(9):1-18
pubmed: 2513473
J Infect Dis. 2004 May 1;189 Suppl 1:S131-45
pubmed: 15106102
MMWR Morb Mortal Wkly Rep. 2018 Jan 12;67(1):33-38
pubmed: 29324728
Hum Vaccin Immunother. 2014;10(5):1373-81
pubmed: 24633360
Pediatrics. 2014 Apr;133(4):577-85
pubmed: 24590750
Vaccine. 2012 Oct 5;30(45):6444-8
pubmed: 22902678
Open Forum Infect Dis. 2018 Oct 04;5(10):ofy199
pubmed: 30302350